Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY275585
Insulin lispro A · 1 trial · 1 indication
Primary outcome measure is based on the pharmacokinetic area under the concentration-time curve from time 0 to the last time point with a measurable concentration.
| Arm | Type | Description |
|---|---|---|
| Insulin Lispro A | EXPERIMENTAL | 20 units (U) subcutaneously (SC) |
| Insulin lispro B | ACTIVE_COMPARATOR | 20 units (U) subcutaneously (SC) |
| Name | Type | Description |
|---|---|---|
| Insulin lispro A | DRUG | 20 units (U) subcutaneously (SC). |
| Insulin lispro B | DRUG | 20 U subcutaneously (SC). |
Inclusion Criteria: * Are healthy males or females. * Body mass index (BMI) between 18.5 and 29.9 kilograms per meter squared (kg/m\^2) * Are nonsmokers. * Have normal blood pressure and pulse rate, a normal electrocardiogram (ECG), and clinical laboratory test results within normal reference range...
Insulin lispro A is an investigational small molecule developed by Eli Lilly and Company. It acts as an agonist at the insulin receptor (INSR). It has been studied in a Phase 1 bioequivalence trial in healthy volunteers. No approved indication has been disclosed for this asset.
Insulin lispro A targets the insulin receptor, also known as INSR. It is classified as an INSR agonist, meaning it activates this receptor. The insulin receptor plays a central role in glucose regulation, and agonism of INSR is the mechanism of action for this investigational agent.
Insulin lispro A is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Eli Lilly is the sponsor of the clinical program for this asset.
Insulin lispro A is in Phase 1 clinical development. It is an investigational drug and has not been approved for any indication. The Phase 1 program consists of one completed trial, with no active trials currently listed.
Insulin lispro A has been evaluated in one completed Phase 1 trial, NCT01133392, titled Bioequivalence of Two Lispro Formulations. The trial enrolled 41 healthy volunteers in Singapore, was randomized and active-controlled, and did not use double blinding. No active trials are listed.